GSK has completed a transformative $10.6B acquisition, adding near-term FDA decision catalysts. Traders should monitor FDA approval decisions on zidesamtinib and neladalkib later this year, which could drive significant upside. Watch for integration costs and potential guidance updates in GSK's next earnings report.
Drugs in focus
GSK drug pipeline →Neladalkib
▲ Bullish Named in this 6-K- Impact
- Phase
- Filed/PDUFA (NDA under FDA Priority Review)
- Time to market
- If approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.
- Next catalyst
- None dated
What to watchFor GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured, Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.
- ● Jideytro 3/10 Approved (FDA); supported by the ARROS-1 phase I/II pivotal trial Named in filing
- ● NVL-330 2/10 Phase 1 Named in filing
- ● Jemperli 5/10 Approved (Phase 3 / registrational Phase 2 for additional indications)
- ● Bexsero 4/10 Approved
- ● Cabenuva 4/10 Approved
- 11 more · All GSK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $51.45entry
- T+1 · 4mo ago +2.57%α +3.11% · $52.77
- T+5 · 4mo ago −1.34%α −0.36% · $50.76
- T+20 · 3mo ago −2.24%α −4.58% · $50.30
- T+60 · 6w ago −9.54%α −12.08% · $46.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK completed its $10.6B acquisition of Nuvalent, adding three lung cancer assets (zidesamtinib, neladalkib, NVL-330) with near-term FDA review decisions. The deal is a major strategic expansion into NSCLC, with multi-blockbuster potential if approved.
Key Facts
- GSK completed acquisition of Nuvalent for aggregate equity value of approximately $10.6 billion (£8.0 billion); net of cash acquired, GSK's aggregate investment is approximately $9.4 billion (£7.1 billion).
- Acquisition adds three lung cancer assets: zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330 (phase I).
- Zidesamtinib and neladalkib are under FDA review for ROS1-positive and ALK-altered NSCLC with target decision dates later this year; both have Breakthrough Therapy and Orphan Drug Designations.
- If approved, assets are expected to launch in 2026 with multi-blockbuster potential.
- GSK CEO Luke Miels highlighted the deal accelerates entry into lung cancer and complements existing pipeline including Ris-Rez (B7-H3 ADC) in phase III.
Financial Impact
Aggregate equity value $10.6B; net cash invested $9.4B, representing ~10% of GSK's market cap.
Risk Factors
- FDA approval risk for zidesamtinib and neladalkib; any adverse regulatory decisions would impair deal value.
- Integration challenges and potential financing dilution if debt or equity issued.
- Competitive landscape in NSCLC targeted therapies (ROS1, ALK, HER2) may limit peak sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006663 |
| Document: 0001654954-26-006663-index-headers.html | 0001654954-26-006663 |
| Document: 0001654954-26-006663-index.html | 0001654954-26-006663 |
| Document: 0001654954-26-006663.txt | 0001654954-26-006663 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers